Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

doi:10.1084/jem.173.3.699

This Article

	Full Text (PDF, 495K)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Sampaio, E. P.
	Articles by Kaplan, G.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Sampaio, E. P.
	Articles by Kaplan, G.


Social Bookmarking

	What's this?

ARTICLES

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

EP Sampaio, EN Sarno, R Galilly, ZA Cohn and G Kaplan
Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021.

Thalidomide selectively inhibits the production of human monocyte tumor necrosis factor alpha (TNF-alpha) when these cells are triggered with lipopolysaccharide and other agonists in culture. 40% inhibition occurs at the clinically achievable dose of the drug of 1 micrograms/ml. In contrast, the amount of total protein and individual proteins labeled with [35S]methionine and expressed on SDS-PAGE are not influenced. The amounts of interleukin 1 beta (IL-1 beta), IL-6, and granulocyte/macrophage colony-stimulating factor produced by monocytes remain unaltered. The selectivity of this drug may be useful in determining the role of TNF-alpha in vivo and modulating its toxic effects in a clinical setting.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Facebook Add to Reddit Reddit Add to Technorati Technorati Twitter What's this?

This article has been cited by other articles:

Keller, M., Sollberger, G., Beer, H.-D. (2009). Thalidomide Inhibits Activation of Caspase-1. J. Immunol. 183: 5593-5599 [Abstract] [Full Text]
Holaday, J. W., Berkowitz, B. A. (2009). Antiangiogenic Drugs: Insights into Drug Development from Endostatin, Avastin and Thalidomide. Mol. Interv. 9: 157-166 [Full Text]
Shah, A., Albrecht, J., Bonilla-Martinez, Z., Okawa, J., Rose, M., Rosenbach, M., Werth, V. P. (2009). Lenalidomide for the Treatment of Resistant Discoid Lupus Erythematosus. Arch Dermatol 145: 303-306 [Abstract] [Full Text]
Noman, A. S. M., Koide, N., Hassan, F., I.-E-Khuda, I., Dagvadorj, J., Tumurkhuu, G., Islam, S., Naiki, Y., Yoshida, T., Yokochi, T. (2009). Thalidomide inhibits lipopolysaccharide-induced tumor necrosis factor-{alpha} production via down-regulation of MyD88 expression. Innate Immunity 15: 33-41 [Abstract]
Lafaras, C., Mandala, E., Verrou, E., Platogiannis, D., Barbetakis, N., Bischiniotis, T., Zervas, K. (2008). Non-thromboembolic pulmonary hypertension in multiple myeloma, after thalidomide treatment: A pilot study. Ann Oncol 19: 1765-1769 [Abstract] [Full Text]
Rogliani, P., Mura, M., Assunta Porretta, M., Saltini, C. (2008). Review: New perspectives in the treatment of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2: 75-93 [Abstract]
Fine, H. A., Kim, L., Albert, P. S., Duic, J. P., Ma, H., Zhang, W., Tohnya, T., Figg, W. D., Royce, C. (2007). A Phase I Trial of Lenalidomide in Patients with Recurrent Primary Central Nervous System Tumors. Clin. Cancer Res. 13: 7101-7106 [Abstract] [Full Text]
Aerbajinai, W., Zhu, J., Gao, Z., Chin, K., Rodgers, G. P. (2007). Thalidomide induces {gamma}-globin gene expression through increased reactive oxygen species mediated p38 MAPK signaling and histone H4 acetylation in adult erythropoiesis. Blood 110: 2864-2871 [Abstract] [Full Text]
Faria, S. C., Ng, C. S., Hess, K. R., Phongkitkarun, S., Szejnfeld, J., Daliani, D., Charnsangavej, C. (2007). CT Quantification of Effects of Thalidomide in Patients with Metastatic Renal Cell Carcinoma. Am. J. Roentgenol. 189: 378-385 [Abstract] [Full Text]
Tabata, C., Tabata, R., Kadokawa, Y., Hisamori, S., Takahashi, M., Mishima, M., Nakano, T., Kubo, H. (2007). Thalidomide Prevents Bleomycin-Induced Pulmonary Fibrosis in Mice. J. Immunol. 179: 708-714 [Abstract] [Full Text]
Mannheim, D., Versari, D., Daghini, E., Gossl, M., Galili, O., Chade, A., Rajkumar, V. S., Ritman, E. L., Lerman, L. O., Lerman, A. (2007). Impaired myocardial perfusion reserve in experimental hypercholesterolemia is independent of myocardial neovascularization. Am. J. Physiol. Heart Circ. Physiol. 292: H2449-H2458 [Abstract] [Full Text]
Bruce, A., Rogers, R. S. III (2007). New and Old Therapeutics for Oral Ulcerations. Arch Dermatol 143: 519-523 [Full Text]
Chen, K.-M., Lai, S.-C. (2007). Biochemical and pathological evaluation of albendazole/thalidomide co-therapy against eosinophilic meningitis or meningoencephalitis induced by Angiostrongylus cantonensis. J Antimicrob Chemother 59: 264-276 [Abstract] [Full Text]
Suvannasankha, A., Fausel, C., Juliar, B. E., Yiannoutsos, C. T., Fisher, W. B., Ansari, R. H., Wood, L. L., Smith, G. G., Cripe, L. D., Abonour, R. (2007). Final Report of Toxicity and Efficacy of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial, HEM01-21. The Oncologist 12: 99-106 [Abstract] [Full Text]
Yndestad, A., Vinge, L. E., Bjornerheim, R., Ueland, T., Wang, J. E., Froland, S. S., Attramadal, H., Aukrust, P., Oie, E. (2006). Thalidomide attenuates the development of fibrosis during post-infarction myocardial remodelling in rats. Eur J Heart Fail 8: 790-796 [Abstract] [Full Text]
Chidlow, J. H. Jr., Langston, W., Greer, J. J.M., Ostanin, D., Abdelbaqi, M., Houghton, J., Senthilkumar, A., Shukla, D., Mazar, A. P., Grisham, M. B., Kevil, C. G. (2006). Differential Angiogenic Regulation of Experimental Colitis. Am. J. Pathol. 169: 2014-2030 [Abstract] [Full Text]
Ye, Q., Chen, B., Tong, Z., Nakamura, S., Sarria, R., Costabel, U., Guzman, J. (2006). Thalidomide reduces IL-18, IL-8 and TNF-{alpha} release from alveolar macrophages in interstitial lung disease. Eur Respir J 28: 824-831 [Abstract] [Full Text]
Scollard, D. M., Adams, L. B., Gillis, T. P., Krahenbuhl, J. L., Truman, R. W., Williams, D. L. (2006). The Continuing Challenges of Leprosy. Clin. Microbiol. Rev. 19: 338-381 [Abstract] [Full Text]
Lee, C. P., Patel, P. M., Selby, P. J., Hancock, B. W., Mak, I., Pyle, L., James, M. G., Beirne, D. A., Steeds, S., A'Hern, R., Gore, M. E., Eisen, T. (2006). Randomized Phase II Study Comparing Thalidomide With Medroxyprogesterone Acetate in Patients With Metastatic Renal Cell Carcinoma. JCO 24: 898-903 [Abstract] [Full Text]
Colleoni, M., Orlando, L., Sanna, G., Rocca, A., Maisonneuve, P., Peruzzotti, G., Ghisini, R., Sandri, M. T., Zorzino, L., Nole, F., Viale, G., Goldhirsch, A. (2006). Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects. Ann Oncol 17: 232-238 [Abstract] [Full Text]
Gullestad, L., Ueland, T., Fjeld, J. G., Holt, E., Gundersen, T., Breivik, K., Folling, M., Hodt, A., Skardal, R., Kjekshus, J., Andreassen, A., Kjekshus, E., Wergeland, R., Yndestad, A., Froland, S. S., Semb, A. G., Aukrust, P. (2005). Effect of Thalidomide on Cardiac Remodeling in Chronic Heart Failure: Results of a Double-Blind, Placebo-Controlled Study. Circulation 112: 3408-3414 [Abstract] [Full Text]
He, M. M., Smith, A. S., Oslob, J. D., Flanagan, W. M., Braisted, A. C., Whitty, A., Cancilla, M. T., Wang, J., Lugovskoy, A. A., Yoburn, J. C., Fung, A. D., Farrington, G., Eldredge, J. K., Day, E. S., Cruz, L. A., Cachero, T. G., Miller, S. K., Friedman, J. E., Choong, I. C., Cunningham, B. C. (2005). Small-Molecule Inhibition of TNF-{alpha}. Science 310: 1022-1025 [Abstract] [Full Text]
Gordon, J.N., Green, S.R., Goggin, P.M. (2005). Cancer cachexia. QJM 98: 779-788 [Abstract] [Full Text]
Hall, S. (2005). The response to injury in the peripheral nervous system. J Bone Joint Surg Br 87-B: 1309-1319 [Full Text]
Yabu, T., Tomimoto, H., Taguchi, Y., Yamaoka, S., Igarashi, Y., Okazaki, T. (2005). Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate. Blood 106: 125-134 [Abstract] [Full Text]
Gordon, J N, Trebble, T M, Ellis, R D, Duncan, H D, Johns, T, Goggin, P M (2005). Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial. Gut 54: 540-545 [Abstract] [Full Text]
Rini, B. I., Small, E. J. (2005). Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma. JCO 23: 1028-1043 [Abstract] [Full Text]
Tadesse, A., Shannon, E. J. (2005). Effects of Thalidomide on Intracellular Mycobacterium leprae in Normal and Activated Macrophages. CVI 12: 130-134 [Abstract] [Full Text]
Moschella, S. L., Kay, J., Mackool, B. T., Liu, V. (2004). Case 35-2004 - A 68-Year-Old Man with End-Stage Renal Disease and Thickening of the Skin. NEJM 351: 2219-2227 [Full Text]
Chung, F., Lu, J., Palmer, B. D., Kestell, P., Browett, P., Baguley, B. C., Tingle, M., Ching, L.-M. (2004). Thalidomide Pharmacokinetics and Metabolite Formation in Mice, Rabbits, and Multiple Myeloma Patients. Clin. Cancer Res. 10: 5949-5956 [Abstract] [Full Text]
Rajkumar, S. V. (2004). Thalidomide: Tragic Past and Promising Future. Mayo Clin Proc. 79: 899-903
Souza, M H L P, Lemos, H. P., Oliveira, R B, Cunha, F Q (2004). Gastric damage and granulocyte infiltration induced by indomethacin in tumour necrosis factor receptor 1 (TNF-R1) or inducible nitric oxide synthase (iNOS) deficient mice. Gut 53: 791-796 [Abstract] [Full Text]
Park, S.-J., Kim, H.-S., Yang, H.-M., Park, K.-W., Youn, S.-W., Jeon, S.-I., Kim, D.-H., Koo, B.-K., Chae, I.-H., Choi, D.-J., Oh, B.-H., Lee, M.-M., Park, Y.-B. (2004). Thalidomide as a Potent Inhibitor of Neointimal Hyperplasia After Balloon Injury in Rat Carotid Artery. Arterioscler. Thromb. Vasc. Bio. 24: 885-891 [Abstract] [Full Text]
Sayarlioglu, M., Kotan, M. C., Topcu, N., Bayram, I., Arslanturk, H., Gul, A. (2004). Treatment of Recurrent Perforating Intestinal Ulcers with Thalidomide in Behcet's Disease. The Annals of Pharmacotherapy 38: 808-811 [Abstract] [Full Text]
Gockel, H. R., Lugering, A., Heidemann, J., Schmidt, M., Domschke, W., Kucharzik, T., Lugering, N. (2004). Thalidomide Induces Apoptosis in Human Monocytes by Using a Cytochrome c-Dependent Pathway. J. Immunol. 172: 5103-5109 [Abstract] [Full Text]
Caradonna, S., Jacobe, H. (2004). Thalidomide as a Potential Treatment for Scleromyxedema. Arch Dermatol 140: 277-280 [Full Text]
LeBlanc, R., Hideshima, T., Catley, L. P., Shringarpure, R., Burger, R., Mitsiades, N., Mitsiades, C., Cheema, P., Chauhan, D., Richardson, P. G., Anderson, K. C., Munshi, N. C. (2004). Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood 103: 1787-1790 [Abstract] [Full Text]
Gee, M. S., Makonnen, S., al-Kofahi, K., Roysam, B., Payvandi, F., Man, H.-W., Muller, G. W., Lee, W. M. F. (2003). Selective Cytokine Inhibitory Drugs with Enhanced Antiangiogenic Activity Control Tumor Growth through Vascular Inhibition. Cancer Res. 63: 8073-8078 [Abstract] [Full Text]
Robinson, N. D., Guitart, J. (2003). Recalcitrant, Recurrent Aphthous Stomatitis Treated With Etanercept. Arch Dermatol 139: 1259-1262 [Full Text]
Ng, S. S. W., Gutschow, M., Weiss, M., Hauschildt, S., Teubert, U., Hecker, T. K., Luzzio, F. A., Kruger, E. A., Eger, K., Figg, W. D. (2003). Antiangiogenic Activity of N-substituted and Tetrafluorinated Thalidomide Analogues. Cancer Res. 63: 3189-3194 [Abstract] [Full Text]
Lu, J., Palmer, B. D., Kestell, P., Browett, P., Baguley, B. C., Muller, G., Ching, L.-M. (2003). Thalidomide Metabolites in Mice and Patients with Multiple Myeloma. Clin. Cancer Res. 9: 1680-1688 [Abstract] [Full Text]
Wilkinson, N, Jackson, G, Gardner-Medwin, J (2003). Biologic therapies for juvenile arthritis. Arch. Dis. Child. 88: 186-191 [Abstract] [Full Text]
Gordon, J N, Goggin, P M (2003). Thalidomide and its derivatives: emerging from the wilderness. Postgrad. Med. J. 79: 127-132 [Abstract] [Full Text]
SCULLY, C., GORSKY, M., LOZADA-NUR, F. (2003). The diagnosis and management of recurrent aphthous stomatitis: A consensus approach. Journal of the American Dental Association 134: 200-207 [Abstract] [Full Text]
Marriott, J. B., Clarke, I. A., Czajka, A., Dredge, K., Childs, K., Man, H.-W., Schafer, P., Govinda, S., Muller, G. W., Stirling, D. I., Dalgleish, A. G. (2003). A Novel Subclass of Thalidomide Analogue with Anti-Solid Tumor Activity in Which Caspase-dependent Apoptosis is Associated with Altered Expression of bcl-2 Family Proteins. Cancer Res. 63: 593-599 [Abstract] [Full Text]
Thomas, P., Walchner, M., Ghoreschi, K., Rocken, M. (2003). Successful Treatment of Granulomatous Cheilitis With Thalidomide. Arch Dermatol 139: 136-138 [Full Text]
Mufti, G., List, A. F., Gore, S. D., Ho, A. Y.L. (2003). Myelodysplastic Syndrome. ASH Education Book 2003: 176-199 [Abstract] [Full Text]
Mathian, A., Amoura, Z., Piette, J.-C. (2002). Pentoxifylline-induced aseptic meningitis in a patient with mixed connective tissue disease. Neurology 59: 1468-1469 [Full Text]
Mohty, M., Stoppa, A.-M., Blaise, D., Isnardon, D., Gastaut, J.-A., Olive, D., Gaugler, B. (2002). Differential regulation of dendritic cell function by the immunomodulatory drug thalidomide. J. Leukoc. Biol. 72: 939-945 [Abstract] [Full Text]
Neben, K., Moehler, T., Benner, A., Kraemer, A., Egerer, G., Ho, A. D., Goldschmidt, H. (2002). Dose-dependent Effect of Thalidomide on Overall Survival in Relapsed Multiple Myeloma. Clin. Cancer Res. 8: 3377-3382 [Abstract] [Full Text]
Bilsborough, J., Uyttenhove, C., Colau, D., Bousso, P., Libert, C., Weynand, B., Boon, T., Van den Eynde, B. J. (2002). TNF-Mediated Toxicity After Massive Induction of Specific CD8+ T Cells Following Immunization of Mice with a Tumor-Specific Peptide. J. Immunol. 169: 3053-3060 [Abstract] [Full Text]
Neben, K., Mytilineos, J., Moehler, T. M., Preiss, A., Kraemer, A., Ho, A. D., Opelz, G., Goldschmidt, H. (2002). Polymorphisms of the tumor necrosis factor-alpha gene promoter predict for outcome after thalidomide therapy in relapsed and refractory multiple myeloma. Blood 100: 2263-2265 [Abstract] [Full Text]
Kinuya, S., Kawashima, A., Yokoyama, K., Koshida, K., Konishi, S., Watanabe, N., Shuke, N., Bunko, H., Michigishi, T., Tonami, N. (2002). Cooperative Effect of Radioimmunotherapy and Antiangiogenic Therapy with Thalidomide in Human Cancer Xenografts. JNM 43: 1084-1089 [Abstract] [Full Text]
Curley, M. J., Hussein, S. A., Hassoun, P. M. (2002). Disseminated Herpes Simplex Virus and Varicella Zoster Virus Coinfection in a Patient Taking Thalidomide for Relapsed Multiple Myeloma. J. Clin. Microbiol. 40: 2302-2304 [Abstract] [Full Text]
Hwu, W.-J., Krown, S. E., Panageas, K. S., Menell, J. H., Chapman, P. B., Livingston, P. O., Williams, L. J., Quinn, C. J., Houghton, A. N. (2002). Temozolomide Plus Thalidomide in Patients With Advanced Melanoma: Results of a Dose-Finding Trial. JCO 20: 2610-2615 [Abstract] [Full Text]
van Deventer, S J H (2002). Small therapeutic molecules for the treatment of inflammatory bowel disease. Gut 50: iii47-53 [Abstract] [Full Text]
Hussein, M. A. (2002). Nontraditional Cytotoxic Therapies for Relapsed/Refractory Multiple Myeloma. The Oncologist 7: 20-29 [Abstract] [Full Text]
Majumdar, S., Lamothe, B., Aggarwal, B. B. (2002). Thalidomide Suppresses NF-{kappa}B Activation Induced by TNF and H2O2, But Not That Activated by Ceramide, Lipopolysaccharides, or Phorbol Ester. J. Immunol. 168: 2644-2651 [Abstract] [Full Text]
Bauditz, J, Wedel, S, Lochs, H (2002). Thalidomide reduces tumour necrosis factor {alpha} and interleukin 12 production in patients with chronic active Crohn's disease. Gut 50: 196-200 [Abstract] [Full Text]
Steins, M. B., Padro, T., Bieker, R., Ruiz, S., Kropff, M., Kienast, J., Kessler, T., Buechner, T., Berdel, W. E., Mesters, R. M. (2002). Efficacy and safety of thalidomide in patients with acute myeloid leukemia. Blood 99: 834-839 [Abstract] [Full Text]
Motzer, R. J., Berg, W., Ginsberg, M., Russo, P., Vuky, J., Yu, R., Bacik, J., Mazumdar, M. (2002). Phase II Trial of Thalidomide for Patients With Advanced Renal Cell Carcinoma. JCO 20: 302-306 [Abstract] [Full Text]
Drenth, J. P. H., Vonk, A. G., Simon, A., Powell, R., van der Meer, J. W. M. (2001). Limited Efficacy of Thalidomide in the Treatment of Febrile Attacks of the Hyper-IgD and Periodic Fever Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial. J. Pharmacol. Exp. Ther. 298: 1221-1226 [Abstract] [Full Text]
Neben, K., Moehler, T., Egerer, G., Kraemer, A., Hillengass, J., Benner, A., Ho, A. D., Goldschmidt, H. (2001). High Plasma Basic Fibroblast Growth Factor Concentration Is Associated with Response to Thalidomide in Progressive Multiple Myeloma. Clin. Cancer Res. 7: 2675-2681 [Abstract] [Full Text]
Raza, A., Meyer, P., Dutt, D., Zorat, F., Lisak, L., Nascimben, F., du Randt, M., Kaspar, C., Goldberg, C., Loew, J., Dar, S., Gezer, S., Venugopal, P., Zeldis, J. (2001). Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98: 958-965 [Abstract] [Full Text]
Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.-T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S. P., Richardson, P. G., Schlossman, R. L., Morgan, G. J., Muller, G. W., Stirling, D. I., Anderson, K. C. (2001). Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood 98: 210-216 [Abstract] [Full Text]
Karim, M Y, Ruiz-Irastorza, G, Khamashta, M A, Hughes, G R. (2001). Update on therapy -- thalidomide in the treatment of lupus. Lupus 10: 188-192 [Abstract]
Verbon, A., Juffermans, N. P., Speelman, P., van Deventer, S. J. H., ten Berge, I. J. M., Guchelaar, H.-J., van der Poll, T. (2000). A Single Oral Dose of Thalidomide Enhances the Capacity of Lymphocytes to Secrete Gamma Interferon in Healthy Humans. Antimicrob. Agents Chemother. 44: 2286-2290 [Abstract] [Full Text]
Baidas, S. M., Winer, E. P., Fleming, G. F., Harris, L., Pluda, J. M., Crawford, J. G., Yamauchi, H., Isaacs, C., Hanfelt, J., Tefft, M., Flockhart, D., Johnson, M. D., Hawkins, M. J., Lippman, M. E., Hayes, D. F. (2000). Phase II Evaluation of Thalidomide in Patients With Metastatic Breast Cancer. JCO 18: 2710-2717 [Abstract] [Full Text]
Little, R. F., Wyvill, K. M., Pluda, J. M., Welles, L., Marshall, V., Figg, W. D., Newcomb, F. M., Tosato, G., Feigal, E., Steinberg, S. M., Whitby, D., Goedert, J. J., Yarchoan, R. (2000). Activity of Thalidomide in AIDS-Related Kaposi's Sarcoma. JCO 18: 2593-2602 [Abstract] [Full Text]
Davey, P.P., Ashrafian, H. (2000). New therapies for heart failure: is thalidomide the answer?. QJM 93: 305-311 [Abstract] [Full Text]
Hellstrom-Lindberg, E., Willman, C., Barrett, A. J., Saunthararajah, Y. (2000). Achievements in Understanding and Treatment of Myelodysplastic Syndromes. ASH Education Book 2000: 110-132 [Abstract] [Full Text]
Kapelushnik, J., Weiss, L., Pappo, O., Okon, E., Or, R. (1999). Thalidomide does not interfere with graft-versus-leukemia reactivity in mice. J Oncol Pharm Pract 5: 179-183 [Abstract]
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., Munshi, N., Anaissie, E., Wilson, C., Dhodapkar, M., Zeldis, J., Barlogie, B., Siegel, D., Crowley, J. (1999). Antitumor Activity of Thalidomide in Refractory Multiple Myeloma. NEJM 341: 1565-1571 [Abstract] [Full Text]
Wolday, D., Akuffo, H., Demissie, A., Britton, S. (1999). Role of Leishmania donovani and Its Lipophosphoglycan in CD4+ T-cell Activation-Induced Human Immunodeficiency Virus Replication. Infect. Immun. 67: 5258-5264 [Abstract] [Full Text]
Reuter, B. K., Wallace, J. L. (1999). Phosphodiesterase inhibitors prevent NSAID enteropathy independently of effects on TNF-alpha release. Am. J. Physiol. Gastrointest. Liver Physiol. 277: G847-G854 [Abstract] [Full Text]
Ridoux, O., Drancourt, M. (1999). Lack of In Vitro Antimicrosporidian Activity of Thalidomide. Antimicrob. Agents Chemother. 43: 2305-2306 [Abstract] [Full Text]
Duong, D. J., Spigel, G. T., Moxley III, R. T., Gaspari, A. A. (1999). American Experience With Low-Dose Thalidomide Therapy for Severe Cutaneous Lupus Erythematosus. Arch Dermatol 135: 1079-1087 [Abstract] [Full Text]
Marriott, J. B., Westby, M., Cookson, S., Guckian, M., Goodbourn, S., Muller, G., Shire, M. G., Stirling, D., Dalgleish, A. G. (1998). CC-3052: A Water-Soluble Analog of Thalidomide and Potent Inhibitor of Activation-Induced TNF-{alpha} Production. J. Immunol. 161: 4236-4243 [Abstract] [Full Text]
Haslett, P. A.J., Corral, L. G., Albert, M., Kaplan, G. (1998). Thalidomide Costimulates Primary Human T Lymphocytes, Preferentially Inducing Proliferation, Cytokine Production, and Cytotoxic Responses in the CD8+ Subset. JEM 187: 1885-1892 [Abstract] [Full Text]
(1998). Clinical Pharmacology of Thalidomide. AIDS Clin Care 1998: 2-2 [Full Text]
Jacobson, J. M., Greenspan, J. S., Spritzler, J., Ketter, N., Fahey, J. L., Jackson, J. B., Fox, L., Chernoff, M., Wu, A. W., MacPhail, L. A., Vasquez, G. J., Wohl, D. A., The National Institute of Allergy and Infectious D, (1997). Thalidomide for the Treatment of Oral Aphthous Ulcers in Patients with Human Immunodeficiency Virus Infection. NEJM 336: 1487-1493 [Abstract] [Full Text]
Zhang, M., Caragine, T., Wang, H., Cohen, P. S., Botchkina, G., Soda, K., Bianchi, M., Ulrich, P., Cerami, A., Sherry, B., Tracey, K. J. (1997). Spermine Inhibits Proinflammatory Cytokine Synthesis in Human Mononuclear Cells: A Counterregulatory Mechanism that Restrains the Immune Response. JEM 185: 1759-1768 [Abstract] [Full Text]
Stevens, R. (1996). The place of thalidomide in the treatment of inflammatory disease. Lupus 5: 257-258
Holm, A. L., Bowers, K. E., McMeekin, T. O., Gaspari, A. A. (1993). Chronic Cutaneous Lupus Erythematosus Treated With Thalidomide. Arch Dermatol 129: 1548-1550 [Abstract]
Fauci, A. (1993). Multifactorial nature of human immunodeficiency virus disease: implications for therapy. Science 262: 1011-1018 [Abstract]
Keifer, J. A., Guttridge, D. C., Ashburner, B. P., Baldwin, A. S. Jr. (2001). Inhibition of NF-kappa B Activity by Thalidomide through Suppression of Ikappa B Kinase Activity. J. Biol. Chem. 276: 22382-22387 [Abstract] [Full Text]